How Many Weeks Does Wegovy Take to Work?

What the STEP 1 trial actually showed about timing

The most reliable window into Wegovy's timeline comes from STEP 1, the pivotal phase-3 trial at 68 weeks. Participants did not reach peak weight loss in week two. The trajectory curved gradually: early weeks brought appetite change and some initial loss, mid-trial months reflected the slower, compounding effect of being at or approaching the 2.4mg maintenance dose, and the greatest separation from placebo appeared in the latter half of the study. The average 15% reduction reported across the full 68-week period is exactly that, a cumulative average, not a six-week result.

That framing matters because a lot of people measure themselves against the headline figure far too early. A question our prescribers hear most weeks is whether the treatment has stopped working when, in reality, the patient is still on the 0.5mg or 1.0mg titration dose and hasn't yet reached the level at which semaglutide's full appetite and metabolic effects take hold. The starting dose exists primarily so your body can adjust; the therapeutic work deepens as the dose does.

If you want a fuller picture of the day-to-day early experience, our page on the first days of Wegovy covers what to expect before the four-week mark.

The titration schedule and why it shapes the results timeline

Wegovy is prescribed on a step-up schedule: 0.25mg for the first four weeks, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg, each step held for roughly a month before the prescriber confirms the next increase. That means a typical patient reaches the full maintenance dose around week twenty. Expecting the same results at week six as week forty is like judging a marathon by the first kilometre.

The dose increases are not arbitrary. Gastrointestinal side effects (nausea, changes in bowel habit, occasional reflux) are most noticeable when the dose goes up, and the slower schedule gives your system time to adapt. Pushing through that adjustment period is part of why patients who complete the full titration tend to see better outcomes than those who stop early because the first few weeks felt underwhelming.

Preparation makes a real difference here. Reading what to do before your first Wegovy dose can help you set realistic expectations and manage the early weeks more comfortably.

When to reassess, and what the guidance says

NICE's appraisal of semaglutide (Wegovy), TA875, includes a clear checkpoint: if a patient has not achieved at least 5% weight loss after six months on the maintenance dose, continuing treatment should be reviewed. That six-month clock starts from maintenance, not from the first injection, which, given the titration schedule, can put the assessment point somewhere around the ten-to-twelve-month mark overall.

For private patients, the same clinical logic applies. Wegovy is not a medicine you either respond to dramatically in week four or abandon. The evidence base was built on nearly a year and a half of treatment. Shorter timelines produce more modest results; that is a feature of the drug's mechanism, not a sign the treatment has failed.

How Wegovy compares to other licensed options over the same kind of timeframe is worth understanding too. The Mounjaro versus Wegovy comparison sets out the head-to-head evidence clearly, including the SURMOUNT-5 findings.

Realistic expectations and the role of lifestyle

Wegovy works by activating GLP-1 receptors that influence appetite signals and slow gastric emptying. It does not override biology entirely. The STEP 1 trial paired semaglutide with a reduced-calorie diet and increased physical activity, and so does the licence. Patients who maintain protein intake and stay active during treatment tend to preserve more lean muscle as weight comes off, which matters for long-term metabolism.

Weeks one to four: appetite begins to shift, food noise quiets. Weeks four to twenty: the dose climbs, the effect deepens. Weeks twenty onwards: most patients are at or near maintenance and the cumulative weight reduction becomes visible. That is the honest arc.

For context on how Wegovy's results compare with oral treatment options, the Wegovy and Ozempic comparison clarifies the licensing distinctions, including why Ozempic is not prescribed for weight loss in the UK, and if you are curious about the efficacy differences between the two, our breakdown of whether Wegovy works better than Ozempic examines what the evidence actually shows. You can also read more about the full range of weight-loss treatment options available through private prescription. If you are already thinking about cost alongside the timeline, our Wegovy cost guide explains what private treatment typically includes. When you are ready to speak with a prescriber, start your free consultation and get a clinical view tailored to your situation.